This is a beta version of OpenPrescribing Hospitals for testing and feedback purposes. Data and functionality may be incomplete. Please contact us if you find any issues or have feedback.
This measure supports work to improve efficiency in hospitals.
The percentage of nivolumab that is issued as the subcutaneous formulation.
We divide the number of products issued of the nivolumab subcutaneous formulation by the total number of products issued of nivolumab. We then multiply that by 100 to obtain the % each month.
Nivolumab can be used in the treatment of a range of common cancers. If given intravenously the infusions can take 30-60 minutes. This uses a lot of nursing time and most importantly the patients time. In April 2025 a new formulation of nivolumab designed to be administered as a subcutaneous injection in a fraction of the time received approval for use in the UK. Although not all patients will be eligible, around two in five of those currently receiving intravenous nivolumab are expected to switch to the new subcutaneous injection and most eligible new patients are also expected to begin on the injectable form of nivolumab.
Trusts are only included in this measure if they have issued any products included in the denominator for this measure.
For this measure, 129/227 Trusts are included. A full list of Trusts included is available on the Submission History page.